How should thrombocytosis be treated, distinguishing reactive from essential forms and specifying first-line cytoreductive therapy?

Treatment of Thrombocytosis

The first critical step is distinguishing reactive (secondary) thrombocytosis from essential thrombocythemia (ET), as reactive thrombocytosis requires no specific platelet-directed therapy—only treatment of the underlying condition—while ET demands risk-stratified cytoreductive therapy with hydroxyurea as the first-line agent for high-risk patients. 1, 2

Distinguishing Reactive from Essential Thrombocytosis

Initial Workup

When thrombocytosis (platelets ≥450 × 10⁹/L) is identified:

• Repeat CBC with differential and peripheral blood smear to confirm persistent elevation and evaluate other cell lines 3
• Check C-reactive protein and ferritin/iron studies to identify inflammatory or iron-deficiency causes of reactive thrombocytosis 3
• Review clinical context: infection, inflammation, malignancy, iron deficiency, recent surgery/trauma, hemolysis, or splenectomy are common causes of reactive thrombocytosis 3, 4

When to Suspect Essential Thrombocythemia

If thrombocytosis persists without an identifiable secondary cause, proceed with:

• JAK2V617F mutation testing (present in ~60% of ET patients) 2, 3
• If JAK2 negative: CALR and MPL mutation testing (CALR in ~25%, MPL in ~3%) 2, 3
• Bone marrow biopsy showing increased mature megakaryocytes in loose clusters, which is essential to exclude prefibrotic myelofibrosis and other myeloproliferative neoplasms 2, 3

Risk Stratification for Essential Thrombocythemia

The revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-Thrombosis) stratifies patients into four risk categories 5, 2, 3:

• Very low risk: Age ≤60 years, no thrombosis history, JAK2 wild-type
• Low risk: Age ≤60 years, no thrombosis history, JAK2 mutation present
• Intermediate risk: Age >60 years, no thrombosis history, JAK2 mutation present
• High risk: Prior thrombosis OR (age >60 years AND JAK2 mutation)

Treatment Algorithm

Very Low-Risk and Low-Risk ET

Observation alone or low-dose aspirin (81-100 mg daily) 5, 1, 2

• Aspirin is recommended if JAK2-mutated or cardiovascular risk factors present 5, 6
• Consider observation only if JAK2 wild-type without cardiovascular risk factors 5
• Cytoreductive therapy is NOT indicated 5, 1

Important caveat: Withhold aspirin if platelet count >1,000-1,500 × 10⁹/L due to acquired von Willebrand disease risk—check ristocetin cofactor and VWF multimers in extreme thrombocytosis 5, 6

Intermediate-Risk ET

Low-dose aspirin (81-100 mg daily) with consideration for cytoreductive therapy 5, 2

Cytoreductive therapy may be considered but is not mandatory unless:

• Progressive splenomegaly
• Uncontrolled disease-related symptoms
• Platelet count >1,500 × 10⁹/L (bleeding risk) 1

High-Risk ET

Cytoreductive therapy PLUS low-dose aspirin (81-100 mg daily) 5, 1, 2

First-Line Cytoreductive Therapy

Hydroxyurea is the first-line cytoreductive agent at any age 1, 2, 3

• Target: normalize platelet counts (typically <400 × 10⁹/L) 5
• Hydroxyurea has demonstrated reduction in thrombotic complications in randomized trials 1
• Long-term use carries a small leukemic transformation risk (5.9% at 8.6 years), but this is significantly lower than with older alkylating agents like pipobroman (16.5% vs 34% at 15 years) 5

Alternative First-Line Options

Pegylated interferon-α should be considered for:

• Young patients (<40 years) where long-term hydroxyurea exposure is concerning 5, 1, 2
• Pregnant patients or women planning pregnancy (hydroxyurea is teratogenic) 6
• Interferon-α achieved 76% complete hematologic response in PV trials and is non-leukemogenic 5

Second-Line Cytoreductive Therapy

If hydroxyurea fails due to resistance or intolerance 1, 7:

1. Anagrelide (preferred second-line for ET) 1, 7, 2
2. Pegylated interferon-α (if not used first-line) 1, 7
3. Busulfan (reserved for elderly patients with short life expectancy due to leukemogenic risk) 1, 2

Avoid pipobroman and ³²P due to high leukemic transformation rates 5, 1

Special Situations

Active Thrombosis

• Therapeutic anticoagulation (LMWH, DOAC, or warfarin) per ACCP guidelines 5
• Initiate or intensify cytoreductive therapy 5
• Consider plateletpheresis for acute life-threatening thrombosis 5

Pregnancy

• Aspirin throughout pregnancy (unless extreme thrombocytosis with acquired VWD) 6
• Interferon-α for all high-risk patients and selected low-risk patients with recurrent fetal loss 6
• Therapeutic LMWH if prior thrombosis history 6
• Maintain strict monitoring; avoid hydroxyurea and warfarin (teratogenic) 6

Extreme Thrombocytosis (>1,500 × 10⁹/L)

• Check for acquired von Willebrand disease before starting aspirin 5, 6, 2
• Cytoreductive therapy indicated due to bleeding risk 5, 1

Perioperative Management

• Normalize platelet counts before elective surgery 5
• High-risk procedures (orthopedic, cardiovascular) require multidisciplinary planning 5
• Extended LMWH prophylaxis for high VTE-risk surgeries 5

Critical Pitfalls to Avoid

1. Do not treat reactive thrombocytosis with cytoreductive therapy—address the underlying cause only 3, 4
2. Do not give aspirin with extreme thrombocytosis without ruling out acquired VWD—paradoxical bleeding risk 5, 6
3. Do not use hydroxyurea in pregnancy or young women planning pregnancy—use interferon-α instead 6
4. Do not use older alkylating agents (pipobroman, busulfan, ³²P) as first-line—significantly higher leukemic transformation risk 5, 1
5. Do not withhold cytoreductive therapy in high-risk patients—over 30% receive no treatment in real-world practice despite clear benefit 8

Cardiovascular Risk Factor Management

All patients require aggressive management of modifiable cardiovascular risk factors 5:

• Smoking cessation
• Hypertension control
• Diabetes management
• Hyperlipidemia treatment

This is as important as platelet-directed therapy for thrombosis prevention.